Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997–1003.
Rizzetto M, Canese MG, Gerin JL, et al. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis. 1980;141:590–602.
Rizzetto M, Hoyer B, Canese MG, et al. delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A. 1980;77:6124–8.
Rizzetto M, Purcell RH, Gerin JL. Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet. 1980;1:1215–8.
Flores R, Ruiz-Ruiz S, Serra P. Viroids and hepatitis delta virus. Semin Liver Dis. 2012;32:201–10.
Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990;8(Suppl):S10–4. discussion S21-13.
Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31–40.
Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32:211–9.
•• Gish RG, Yi DH, Kane S, et al. Coinfection with Hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013;28(9):1521–5. This is the first epidemiological study of hepatitis delta in the US in >10 years; it provides data from a large patient-based population with a multitude of risk factors. The higher than expected prevalence supports revising screening guidelines to advocate for all patients with HBV to be screened for HDV in order both to give the individual patient important information related to the possible need for treatment, and to support the public health goal of reducing transmission by educating HDV-negative patients about the need for protection against superinfection and HDV-infected patients about the need to protect against transmission to others.
Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202:845–52.
Stroffolini T, Almasio PL, Sagnelli E, et al. Evolving clinical landscape of chronic hepatitis B: a multicenter Italian study. J Med Virol. 2009;81:1999–2006.
Alvarado-Mora MV, Locarnini S, Rizzetto M, et al. An update on HDV: virology, pathogenesis and treatment. Antivir Ther. 2013;18:541–8.
Dunford L, Carr MJ, Dean J, et al. A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PloS One. 2012;7:e39027.
Braga WS, Castilho Mda C, Borges FG, et al. Hepatitis D virus infection in the Western Brazilian Amazon - far from a vanishing disease. Rev Soc Bras Med Trop. 2012;45:691–5.
Lunel-Fabiani F, Mansour W, Amar AO, et al. Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: A cross sectional study. J Infect. 2013;67(5):448–57.
Bakhshipour A, Mashhadi M, Mohammadi M, et al. Seroprevalence and risk factors of hepatitis delta virus in chronic hepatitis B virus infection in Zahedan. Acta Med Iran. 2013;51:260–4.
Amini N, Alavian SM, Kabir A, et al. Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis. Hepat Mon. 2013;13:e8210.
Nguyen VT, McLaws ML, Dore GJ. Highly endemic hepatitis B infection in rural Vietnam. J Gastroenterol Hepatol. 2007;22:2093–100.
Tran HT, Ushijima H, Quang VX, et al. Prevalence of hepatitis virus types B through E and genotypic distribution of HBV and HCV in Ho Chi Minh City, Vietnam. Hepatol Res. 2003;26:275–80.
Gomaa NI, Metwally LA, Nemr N, et al. Seroprevalence of HDV infection in HBsAg positive population in Ismailia, Egypt. Egypt J Immunol. 2013;20:23–8.
Saravanan S, Madhavan V, Velu V, et al. High prevalence of hepatitis delta virus among patients with chronic hepatitis B virus infection and HIV-1 in an intermediate hepatitis B virus endemic region. J Int Assoc Provid AIDS Care. 2013. doi:10.1177/2325957413488166.
Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59(5):949–56.
Ho E, Deltenre P, Nkuize M, et al. Coinfection of hepatitis B and hepatitis delta virus in Belgium: a multicenter BASL study. Prospective epidemiology and comparison with HBV mono-infection. J Med Virol. 2013;85:1513–7.
William Tong CY, Asher R, Toby M, et al. A re-assessment of the epidemiology and patient characteristics of hepatitis D virus infection in inner city London. J Infect. 2013;66:521–7.
Popescu GA, Otelea D, Gavriliu LC, et al. Epidemiology of hepatitis D in patients infected with hepatitis B virus in bucharest: a cross-sectional study. J Med Virol. 2013;85:769–74.
Rivas P, Herrero MD, Poveda E, et al. Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea living in Spain. Am J Trop Med Hyg. 2013;88:789–94.
Shadur B, Maclachlan J, Cowie B. Hepatitis D virus in Victoria 2000-2009. Intern Med J. 2013;43(10):1081–7.
Farci P. Delta hepatitis: an update. J Hepatol. 2003;39 Suppl 1:S212–9.
Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228–36.
Kew MC. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J Viral Hepat. 2013;20:149–57.
Olivero A, Smedile A. Hepatitis delta virus diagnosis. Semin Liver Dis. 2012;32:220–7.
Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.
• Katsoulidou A, Manesis E, Rokka C, et al. Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D. J Viral Hepat. 2013;20:256–62. This paper is important because we currently have no standardized PCR assays; a standardized assay is needed to be able to compare data outputs around the world andto cross-link studies.
Brichler S, Le Gal F, Butt A, et al. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia. Clin Gastroenterol Hepatol. 2013;11:734–40.
Kodani M, Martin A, Mixson-Hayden T, et al. One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. J Virol Methods. 2013;193:531–5.
• Calle Serrano B, Heidrich B, Homs M, et al. Development and evaluation of a Baseline Event-Anticipation (BEA)-score for hepatitis delta. Hepatology. 2011;54:444. This manuscript is important because the authors developed a sophisticated but very usable scoring system to assist with prognostication.
Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32:237–44.
Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005;22:227–32.
Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. 1994;14:154–7.
Yurdaydin C, Bozkaya H, Gurel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol. 2002;37:266–71.
Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology. 1999;30:546–9.
Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–31.
Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep. 2013;15:31–8.
•• Heidrich B, Yurdaydin C, Kabacam G, et al. Long-term follow-up after Peg-IFNa2a-based therapy of chronic hepatitis delta. J Hepatol. 2013;58:S20. This paper is very important because of the final data showing only a 15 % long-term cure rate for HDV, whereas historically there were publications that proposed cure rates of 30 % or higher. The study provides clear evidence that we need new targeted therapies for HDV.
Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330:88–94.
Lamers MH, Kirgiz OO, Heidrich B, et al. Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther. 2012;17:1029–37.
Alavian SM, Tabatabaei SV, Behnava B, et al. Standard and pegylated interferon therapy of HDV infection: a systematic review and meta- analysis. J Res Med Sci. 2012;17:967–74.
Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713–20.
Ormeci N, Bolukbas F, Erden E, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology. 2011;58:1648–53.
Kabacam G, Dalekos GN, Cakaloglu Y, et al. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol. 2012;23:560–8.
Sanchez-Tapias JM, Mas A, Costa J, et al. Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis. J Hepatol. 1987;5:205–10.
Heller T, Hoofnagle JH. Denying the wolf access to sheep's clothing. J Clin Invest. 2003;112:319–21.
Glenn JS, Watson JA, Havel CM, et al. Identification of a prenylation site in delta virus large antigen. Science. 1992;256:1331–3.
Lutgehetmann M, Mancke LV, Volz T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685–94.
Mahtab MA, Bazinet M, Vaillant A. REP 9 AC: a potent HBsAg release inhibitor that can rapidly restore immunocompetence in patients with chronic hepatitis B. Hepatology. 2010;52:559A–60.
Mahtab MA, Bazinet M, Vaillant A. REP 9AC: a potent HBsAg release inhibitor that can rapidly restore immunocompetence in patients with chronic hepatitis B. The 61st Annual Meeting of the American Association for the Study of Liver Diseases; Boston, Massachusetts; Oct 29-Nov 2, 2010.
Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013;21:973–85.
Grabowski J, Yurdaydin C, Zachou K, et al. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int. 2011;31:1395–405.
Roethle PA, McFadden RM, Yang H, et al. Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis. J Med Chem. 2013;56(18):7324–33.
Ciancio A, Rizzetto M. Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol. 2013. doi:10.1038/nrgastro.2013.164.
Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15:314–21.
Yurdaydin C, Bozkaya H, Karaaslan H, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat. 2007;14:812–6.
Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–35.